Literature DB >> 2318536

Differences in susceptibilities of the lymphogranuloma venereum and trachoma biovars of Chlamydia trachomatis to neutralization by immune sera.

E M Peterson1, M Hoshiko, B A Markoff, M W Lauermann, L M de la Maza.   

Abstract

Sera from seven patients from whom a C. trachomatis serovar L2 strain was isolated were tested in vitro for their ability to neutralize the infectivity of this organism. In one patient an inguinal lymph node was culture positive, whereas the remaining six patients had positive rectal biopsies. Sera from four of the patients, including the patient with the lymph node isolate, failed to neutralize serovar L2(434). In addition, the homologous strain recovered from the inguinal lymph node was available and was resistant to neutralization by the homologous sera. However, the same sera effectively neutralized a trachoma serovar, E(Bour). All four sera had inclusion immunofluorescent-antibody titers to C. trachomatis serovar L2 of 2,048 to 16,384 and microimmunofluorescent-antibody titers to the lymphogranuloma venereum biovar were equal or higher in all cases than to the 12 serovars of the trachoma biovar. The three remaining sera, while neutralizing the infectivity of the L2 strains tested, neutralized serovar E to a greater extent. These sera had the same inclusion immunofluorescent antibody titers as the sera that failed to neutralize serovar L2. To see whether this difference in the sensitivity of the biovars toward neutralization could be characterized, sera were obtained from mice immunized with different doses of both serovars L2 and E. Sera obtained from mice immunized with serovar E were able to effectively neutralize the homologous strain. In contrast, neutralization of the immunizing strain, L2(UCI-20), was not seen with sera obtained on days 7, 14, and 21 after immunization from animals receiving 8 x 10(5) and 8 x 10(4) inclusion-forming units of L2(UCI-20); however, these same sera neutralized serovar E. However, with a higher immunizing dose of L2 (10(7) IFUs), both E and L2 were neutralized with sera obtained 7 and 14 days after immunization. Therefore, the relative resistance to neutralization by serovar L2 compared with that of serovar E in the mouse model was inoculum dependent.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2318536      PMCID: PMC258564          DOI: 10.1128/iai.58.4.938-943.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  12 in total

1.  Differential antimicrobial activity of human mononuclear phagocytes against the human biovars of Chlamydia trachomatis.

Authors:  E C Yong; E Y Chi; C C Kuo
Journal:  J Immunol       Date:  1987-08-15       Impact factor: 5.422

Review 2.  Molecular basis for serum resistance in Neisseria gonorrhoeae.

Authors:  P A Rice
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

3.  Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity.

Authors:  E M Peterson; G M Zhong; E Carlson; L M de la Maza
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

Review 4.  Bactericidal and bacteriolytic activity of serum against gram-negative bacteria.

Authors:  P W Taylor
Journal:  Microbiol Rev       Date:  1983-03

5.  Immunotyping of Chlamydia trachomatis with monoclonal antibodies.

Authors:  S P Wang; C C Kuo; R C Barnes; R S Stephens; J T Grayston
Journal:  J Infect Dis       Date:  1985-10       Impact factor: 5.226

6.  Gonococci causing disseminated gonococcal infection are resistant to the bactericidal action of normal human sera.

Authors:  G K Schoolnik; T M Buchanan; K K Holmes
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

7.  Systemic Chlamydia trachomatis infection in mice: a comparison of lymphogranuloma venereum and trachoma biovars.

Authors:  R C Brunham; C Kuo; W J Chen
Journal:  Infect Immun       Date:  1985-04       Impact factor: 3.441

8.  Role of endogenous gamma interferon in host defense against Chlamydia trachomatis infections.

Authors:  G M Zhong; E M Peterson; C W Czarniecki; R D Schreiber; L M de la Maza
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

9.  Restriction endonuclease analysis of DNA from Chlamydia trachomatis biovars.

Authors:  E M Peterson; L M de la Maza
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

10.  Characterization of Chlamydia DNA by restriction endonuclease cleavage.

Authors:  E M Peterson; L M de la Maza
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

View more
  5 in total

1.  Early complement components enhance neutralization of Chlamydia trachomatis infectivity by human sera.

Authors:  J S Lin; L L Yan; Y Ho; P A Rice
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

2.  Specific-pathogen-free pigs as an animal model for studying Chlamydia trachomatis genital infection.

Authors:  Daisy Vanrompay; Thi Q T Hoang; Liselotte De Vos; Kristel Verminnen; Taher Harkinezhad; Koen Chiers; Servaas A Morré; Eric Cox
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Characterization of the humoral response induced by a peptide corresponding to variable domain IV of the major outer membrane protein of Chlamydia trachomatis serovar E.

Authors:  X Cheng; S Pal; L M de la Maza; E M Peterson
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

4.  Characterization of kinetics and target proteins for binding of human complement component C3 to the surface-exposed outer membrane of Chlamydia trachomatis serovar L2.

Authors:  R T Hall; T Strugnell; X Wu; D V Devine; H G Stiver
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

5.  Chlamydia trachomatis L2c Infection in a Porcine Model Produced Urogenital Pathology and Failed to Induce Protective Immune Responses Against Re-Infection.

Authors:  Evelien De Clercq; Matthias Van Gils; Katelijn Schautteet; Bert Devriendt; Celien Kiekens; Koen Chiers; Wim Van Den Broeck; Eric Cox; Deborah Dean; Daisy Vanrompay
Journal:  Front Immunol       Date:  2020-10-26       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.